近日,无锡药明康德新药开发股份有限公司(简称“药明康德”)抛出两则重磅消息:一是拟以28亿元的基准对价,向高瓴投资旗下基金新设实体出售上海康德弘翼医学临床研究有限公司(简称“康德弘翼”)、上海药明津石医药科技有限公司(简称“津石医药”)两家临床服务子公司100%股权;其次披露今年前三季度业绩数据,实现营收328.57亿元、归母净利润120.76亿元,同比增幅分别达18.61%和84.84%。在业绩...
Source Link近日,无锡药明康德新药开发股份有限公司(简称“药明康德”)抛出两则重磅消息:一是拟以28亿元的基准对价,向高瓴投资旗下基金新设实体出售上海康德弘翼医学临床研究有限公司(简称“康德弘翼”)、上海药明津石医药科技有限公司(简称“津石医药”)两家临床服务子公司100%股权;其次披露今年前三季度业绩数据,实现营收328.57亿元、归母净利润120.76亿元,同比增幅分别达18.61%和84.84%。在业绩...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.